Market Overview

A Peek Into The Market Before The Trading Starts

A Peek Into The Market Before The Trading Starts
Related WDC
Argus: Western Digital Poised To Beat The Market After Cash Infusion
Benzinga's Top Upgrades
Technology Stock Roundup: GOOGL Event, AMZN Ban, TWTR CEO (Zacks)
Related BIIB
Historical Biotech IPO Data From The 'Godfather Of Biotechnology'
Trans Pacific Trade Pact Finally Agreed
Acorda Soars, Settles Ampyra Patent Dispute with Allergan (Zacks)

Pre-open movers US stock futures are higher this morning. Futures for the Dow Jones Industrial Average surged 30 points to 13,295.00 and S&P 500 index futures rose 4.60 points to 1,433.00. Nasdaq 100 futures gained 4.75 points to 2,718.00.

A Peek Into Global Markets European markets were lower today. The STOXX Europe 600 Index fell 0.16%, London's FTSE 100 Index dropped 0.16%, French CAC 40 Index declined 0.11% and German DAX 30 index fell 0.17%.

Asian markets ended mixed, with Japan's Nikkei Stock Average dropping 0.15%, China's Shanghai Composite gaining 0.10% and Australia's S&P/ASX 200 rising 0.11%. Hong Kong's Hang Seng index rose 0.65% and India's Sensex dropped 0.69%.

Broker Recommendation Analysts at Citigroup downgraded Western Digital (NASDAQ: WDC) from “buy” to “sell.” The target price for Western Digital has been lowered from $53 to $32.

Western Digital shares dropped 1.07% to $36.20 in pre-market trading.

Breaking news

  • Biogen Idec (NASDAQ: BIIB) announced new data from studies evaluating oral BG-12 (dimethyl fumarate), which provide further evidence supporting its strong clinical and radiological effects in people with relapsing-remitting multiple sclerosis (RRMS) and reinforce its favorable safety profile seen to date. To read the full news, click here.
  • LINN Energy LLC (NASDAQ: LINE) announced today the pricing of the initial public offering of 30,250,000 common shares of LinnCo LLC (NASDAQ: LNCO), a wholly-owned subsidiary of LINN, at $36.50 per common share. To read the full news, click here.
  • Lexicon Pharmaceuticals (NASDAQ: LXRX) announced positive, top-line data from a recently completed Phase 2 study in carcinoid syndrome with telotristat etiprate. To read the full news, click here.
  • AU Optronics (NYSE: AUO) signed patent cross-license agreements with E-Ink Holdings and Hydis Technologies Co Ltd, E-Ink's South Korean subsidiary, respectively. To read the full news, click here.

Posted-In: Citigroup US Stock FuturesNews Futures Global Pre-Market Outlook Markets


Related Articles (BIIB + AUO)

Get Benzinga's Newsletters